References
- Aghemo, A., & De francesco, R. (2013). New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology, 58, 428–438. doi: 10.1002/hep.26371
- Allan, R., Thoirs, K., & Phillips, M. (2010). Accuracy of ultrasound to identify chronic liver disease. World Journal of Gastroenterology, 16, 3510–3520. doi: 10.3748/wjg.v16.i28.3510
- Bedossa, P., & Poynard, T. (1996). An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 24, 289–293. doi: 10.1002/hep.510240201
- Bonacini, M. (2011). Alcohol use among patients with HIV infection. Annals of Hepatology, 10, 502–507.
- Crum-Cianflone, N., Dilay, A., Collins, G., Dean, A., Campin, R., Medina, S., … Goodman, S. (2009). Nonalcoholic fatty liver disease (NAFLD) among HIV-infected persons. Journal of Acquired Immune Deficiency Syndromes, 50, 464–473. doi: 10.1097/QAI.0b013e318198a88a
- McGovern, B., Ditelberg, J., Taylor, L., Gandhi, R., Christopoulos, K., Chapman, S., … Schwartzapfel, B. (2006). Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clinical Infectious Diseases, 43, 365–372. doi: 10.1086/505495
- Mohammed, S. S., Aghdassi, E., Salit, I. E., Avand, G., Sherman, S., Guindi, M. (2007). HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. Journal of Acquired Immune Deficiency Syndromes, 45, 432–438. doi: 10.1097/QAI.0b013e318074efe3
- Morlat, P., Roussillon, C., Henard, S., Salmon, D., Bonnet, F., Cacoub, P., … Georget, A. (2014). Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS, 28, 1181–1191.
- Morse, C. G., McLaughlin, M., Matthews, L., Proschan, M., Thomas, F., Gharib, A. M., … alAbu-Asab, M. (2015). Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clinical Infectious Diseases, 60, 1569–1578.
- Price, J. C., Seaberg, E. C., Latanich, R., Budoff, M. J., Kingsley, L. A., Palella, F. J. Jr, … Witt, M. D. (2014). Risk factors for fatty liver in the multicenter AIDS cohort study. The American Journal of Gastroenterology, 109, 695–704. doi: 10.1038/ajg.2014.32
- Rao, M. N., Lee, G. A., & Grunfeld, C. (2006). Metabolic abnormalities associated with the use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors. American Journal of Infectious Diseases, 2, 159–166. doi: 10.3844/ajidsp.2006.159.166
- Sheron, N., Gilmore, I., Parsons, C., Hawkey, C., Rhodes, J. (2012). Projections of alcohol-related deaths in England and wales – tragic toll or potential prize? Lancet, 379, 687–688. doi: 10.1016/S0140-6736(12)60244-X
- Tan, Y., Fisher, M., Gilleece, Y., & Verma, S. (2015). Non viral liver disease burden in HIV positive individuals. A prospective cohort study: preliminary results. Poster presentation at European AIDS conference, Barcelona.
- Williams, R., Aspinall, R., Bellis, M., Camps-Walsh, G., Cramp, M., Dhawan, A., … Ferguson, J. (2014). Addressing liver disease in the UK: A blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet, 6736, 61838–9.